Tsumura & Co. (TYO:4540)
4,186.00
+56.00 (1.36%)
Jan 23, 2026, 3:30 PM JST
Tsumura & Co. Revenue
Tsumura & Co. had revenue of 46.80B JPY in the quarter ending September 30, 2025, with 3.13% growth. This brings the company's revenue in the last twelve months to 181.92B, up 10.51% year-over-year. In the fiscal year ending March 31, 2025, Tsumura & Co. had annual revenue of 181.09B with 20.05% growth.
Revenue (ttm)
181.92B
Revenue Growth
+10.51%
P/S Ratio
1.69
Revenue / Employee
42.58M
Employees
4,272
Market Cap
307.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 181.09B | 30.25B | 20.05% |
| Mar 31, 2024 | 150.85B | 10.80B | 7.71% |
| Mar 31, 2023 | 140.04B | 10.50B | 8.10% |
| Mar 31, 2022 | 129.55B | -1.34B | -1.02% |
| Mar 31, 2021 | 130.88B | 7.64B | 6.19% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Toho Holdings | 1.53T |
| Sumitomo Pharma | 445.21B |
| Towa Pharmaceutical | 266.67B |
| Sawai Group Holdings | 200.00B |
| Nippon Shinyaku | 160.55B |
| Hisamitsu Pharmaceutical Co. | 159.27B |
| KYORIN Pharmaceutical | 133.68B |
| Mochida Pharmaceutical | 109.05B |